Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction

NCT07288398 is registered in ClinicalTrials.gov with Tenax Therapeutics, Inc. as lead sponsor.

NCT NCT07288398
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07288398 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction
Lead sponsor
Tenax Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
March 3, 2026
Completion date
June 30, 2029
Enrollment
540 (estimated)
Sites
141

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary hypertension associated with hfpef